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The purpose of this study was to determine the effects of PCBs and PBBs on peroxisome proliferator-activated receptor-
α-(PPARα-) associated enzyme activities or protein levels. Male Sprague-Dawley rats were administered a single IP injec-
tion (150 μmol/kg) of either 3,3’,4,4’-tetrabromobiphenyl, 3,3’,4,4’-tetrachlorobiphenyl, 3,3’,5,5’-tetrabromobiphenyl, 2’,3,3’,4,5-
pentachlorobiphenyl, 3,3’,4,4’,5-pentachlorobiphenyl, 2,2’,3,3’,5,5’-hexachlorobiphenyl, or 3,3’,4,4’,5,5’-hexabromobiphenyl in
corn oil (10ml/kg). One week later, the activities of catalase, peroxisomal fatty acyl-CoA oxidase, and peroxisomal beta-oxidation
as well as cytochrome P450 4A (CYP4A) protein content were determined in subcellular liver fractions. None of the peroxisomal
enzyme activities were significantly increased by any of the halogenated biphenyl congeners tested. Except for minor (approx. 25%)
increases in the total CYP4A content following treatment with 2,2’,3,3’,5,5’-hexachlorobiphenyl and 3,3’,5,5’-tetrabromobiphenyl,
CYP4A protein contents were not increased by any treatment. The two Ah receptor agonists, 3,3’,4,4’-tetrabromobiphenyl and
3,3’,4,4’,5-pentachlorobiphenyl, significantly diminished the liver content of CYP4A proteins and activities of the peroxisomal en-
zymes studied. Since a range of congeners with different biologic and toxicologic activities were selected for this study, it may be
concluded that the polyhalogenated biphenyls do not induce peroxisome proliferation in the male rat, but rather certain members
of this class of compounds down regulate peroxisome-associated enzymes. Since PCBs and PBBs do not increase enzyme activities
and expression of proteins associated with PPARα, these agents are therefore exerting their carcinogenic and promoting activities
by some other mechanism.
Copyright © 2007 Larry W. Robertson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The administration of any of a diverse class of chemi-
cals, including plasticizers, hypolipidemic drugs, and per-
fluorinated fatty acids, leads to the activation of the per-
oxisome proliferator-activated receptor-α (PPARα), the ex-
pression of peroxisomal and nonperoxisomal proteins, and
upon chronic administration, the induction of hepatic tu-
mors in rodents [1]. These chemicals, known as peroxisome
proliferators or peroxisome proliferator-activated receptor-
α (PPARα) agonists, strongly increase both the number
of peroxisomes in the rodent liver and the relative vol-
ume of the liver occupied by these organelles. The spe-
cific peroxisomal enzymes enhanced include the enzymes of
fatty acid beta-oxidation and the carnitine acyl transferases
[2].
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Peroxisome proliferation is also accompanied by an in-
crease in enzymes which are not directly associated with the
organelle, including the members of the CYP4A gene sub-
family which catalyze lauric acid hydroxylation [3, 4]. The
induction of cytochrome P450 4A (CYP4A) isozymes in-
evitably accompanies peroxisome proliferation in the rodent,
an effect which has been seen with a broad range of peroxi-
some proliferators, and it has been suggested that CYP4A and
peroxisomal enzymes are coordinately regulated [1].
The polyhalogenated biphenyls, PCBs, and PBBs, are
other classes of hepatic carcinogens that have profound ef-
fect on gene expression. PBBs and PCBs possessing no ortho
halogens are efficacious inducers of CYP1A and many other
enzymes, and avidly bind the aryl hydrocarbon (Ah) recep-
tor [5]. Ortho-para-substituted PBBs and PCBs activate the
constitutive androstane receptor (CAR) and pregnane X re-
ceptor (PXR) and induce CYP2B and CYP3A enzymes [6–
8]. Like the peroxisome proliferators, halogenated biphenyls
are efficacious promoters of two-stage hepatocarcinogenesis
[9, 10], and are active as liver carcinogens in chronic bioas-
says [10, 11].
One possible mechanism for the chronic activities of
PCBs and PBBs is the acute action of these compounds on
the enzymes associated with PPARα. Previously, Borlakoglu
et al. [12] found that PCBs increased CYP4A-related lauric
acid hydroxylation and CYP4A1 protein levels. We therefore
hypothesized that PCBs and PBBs may influence the activa-
tion of PPARα and thus influence the enzyme activities or
protein levels of PPARα-associated proteins. In the present
study, the effects of several selected congeneric polyhalo-
genated biphenyls, representing different classes of enzyme
inducers, on peroxisomal enzyme activities and CYP4A pro-
tein levels are reported.
2. MATERIALS AND METHOD
2.1. Chemicals
3,3′,4,4′-Tetrachlorobiphenyl (PCB-77), 2′,3,3′,4,5,-penta-
chlorobiphenyl (PCB-122), 3,3′,4,4′,5-pentachlorobiphenyl
(PCB-126), 3,3′, 4,4′-tetrabromobiphenyl (PBB-77), 3,3′,
5,5′-tetrabromobiphenyl (PBB-80), and 3,3′,4,4′,5,5,′-
hexabromobiphenyl (PBB-169) were synthesized as previ-
ously described [13, 14]. 2,2′,3,3′,5,5′-Hexachlorobiphenyl
(PCB-133) was prepared via a multistep synthesis involving
the chlorination of 2,2′,5,5′-tetrachlorobenzidine with
N-chlorosuccinimide and subsequent deamination with
hypophosphorous acid, as described by Kubiczak et al. [15].
The synthetic polyhalogenated biphenyl congeners were
purified by Florisil (Macherey-Nagel, Duren, Germany) and
Alumina (Aluminiumoxid 90, Merck, Darmstadt, Germany)
chromatography and recrystallization from methanol.
Structural assignments were confirmed by nuclear magnetic
resonance spectrometry and mass spectroscopy. The purity
of the individual congeners was >97%.
2.2. Experimental design
48 male Sprague-Dawley rats (approx. 40 g) were purchased
from Harlan Sprague Dawley (Indianapolis, Ind, USA). The
rats were randomly distributed into different groups (6 rats
per group) and were placed on a purified diet similar to
the AIN-76A diet [16, 17], which consisted of corn starch,
32.5%; dextrose, 32.5%; vitamin-free casein, 20.0%; cellulose
fiber, 5.0%; corn oil, 5.0%; AIN mineral mix, 3.5%; AIN vi-
tamin mix, 1.0%; DL-methionine, 0.3%; choline bitartrate,
0.2%. All dietary components were purchased from Teklad
(Madison, Wis, USA). After 1 month, each animal (average
weight: 230 g) was administered a single IP injection of a con-
generic polyhalogenated biphenyl (150 μmol/kg) in corn oil
(10mI/kg) or vehicle alone. The route of administration (IP),
chosen to maximize delivery of the xenobiotic and minimize
the contamination of facilities, and the time course of the
experiment have been routinely used for expression studies
with halogenated biphenyls (please see, e.g., [8]). One week
after the administration of the halogenated biphenyl, each
rat was euthanized with pentobarbital (120mg/kg, IP). The
liver was excised and homogenized with an Ultra-Turrax ho-
mogenizer (Tekmar Co. Cincinnati, Ohio, USA) in 4 volumes
of 1.15% KCl-potassium phosphate buffer (0.05M; pH 7.4).
Aliquots of the homogenate were used for the determination
of protein [18], and the activities of catalase [19], peroxiso-
mal beta-oxidation [20], and fatty acyl-CoA oxidase [21], es-
sentially as described. Hepatic 10 000 xg supernatants were
prepared [22] and used for cytochrome P450 analyses, as de-
scribed below.
2.3. Western analyses
Equal volumes of liver 10 000 xg supernatants from all ani-
mals per treatment group were combined. Aliquots contain-
ing 50 μg of protein per lane were subjected to 10% SDS-
PAGE [23] and blotted onto nitrocellulose as described by
Towbin et al. [24]. The Western blots were incubated with
1 μg/ml of primary monoclonal mouse antibody followed
by incubation with a sheep antimouse IgG-horseradish-
peroxidase conjugate. Staining was performedwith 4-chloro-
l-naphthol in the presence of hydrogen peroxide. The mono-
clonal antibody “clo4” is diagnostic for rat liver cytochrome
P450 isozymes CYP4Al, CYP4A2, and CYP4A3, and was
raised and characterized as described previously [25, 26].
Quantitation of CYP4A isozymes was carried out by densit-
ometric scanning using a CAMAG II TLC scanner with Cat
software Version 3.05. Results are expressed as integrated ab-
sorption units per 50 μg 10 000 xg supernatant protein.
2.4. Statistical analyses
Data were analyzed by one-way analysis of variance andDun-
nett’s multiple comparison test [27].
3. RESULTS AND DISCUSSION
The activities of the enzymes catalase and fatty acyl-CoA
oxidase, which are located within or attached to the mem-
brane of the peroxisome, as well as the measurement of the
flux through the peroxisomal beta-oxidation pathway are
all highly specific peroxisomal activities. In male rats, fatty
acyl-CoA oxidase and peroxisomal beta-oxidation increase
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Table 1: Effect of PCBs on PPARα-related enzyme activities and protein levels.
Treatment Catalase (units/mg/min) FAO (nmol/mg/min)
Peroxisomal
β-oxidation
(nmol/mg/min)
Total CYP4A (densitometry units)a
Control 418± 96 2.73± 0.43 2.93± 0.43 2354
PCB-77 355± 75 2.66± 0.27 2.28± 0.22 2301
PCB-122 411± 47 2.58± 0.22 2.96± 0.62 1562
PCB-126 179± 42∗ 0.69± 0.20∗ 1.62± 0.42∗ 1902
PCB-133 412± 62 2.73± 0.29 2.61± 0.69 2898
Values are means ± SEM. Values significantly different from the control value are labeled with an asterisk (∗), P < .05.
a Equal volumes of liver 10 000 xg supernatants from all animals per treatment group were combined; values represent the densitometric tracing from one
lane.
Table 2: Effect of PCBs on PPARα-related enzyme activities and protein levels.
Treatment Catalase (units/mg/min) FAO (nmol/mg/min)
Peroxisomal
β-oxidation
(nmol/mg/min)
Total CYP4A (densitometry units)a
Control 418± 96 2.73± 0.43 2.93± 0.43 1970
PBB-77 302± 73∗ 0.67± 0.32∗ 1.34± 0.34∗ 1042
PBB-80 429± 81 3.10± 0.30 2.31± 0.46 2473
PBB-169 380± 33 1.89± 0.23∗ 1.89± 0.23∗ 927
Values are means ± SEM. Values significantly different from the control value are labeled with an asterisk (∗), P < .05.
a Equal volumes of liver 10 000 xg supernatants from all animals per treatment group were combined; values represent the densitometric tracing from one
lane.
10–20-fold when potent peroxisome proliferators are admin-
istered, whereas catalase increases about 2-fold [2]. We have
studied the regulation of these enzyme activities following
application of structurally unrelated peroxisome prolifera-
tors and related xenobiotics [28–30]. None of the PCBs tested
in the present study increased any of these activities (Table 1).
Instead, the most potent Ah receptor agonist, PCB-126, sig-
nificantly reduced the activities of fatty acyl-CoA oxidase and
peroxisomal beta-oxidation, an observation which suggests
that these halogenated biphenyls may diminish the liver’s
ability to break down long-chain fatty acids. Indeed, these
compounds cause the concentration of neutral lipids within
the liver of rats (fatty liver) (please see below). PCB-126 also
lowered catalase activity. PCB-133 was the only PCB used to
increase total CYP4A protein: to 123% of the control value
as evidenced by immunoblot analysis. The other PCBs dis-
played either no effect (PCB-77), or slightly (PCB-126) or
markedly (PCB-122) reduced total hepatic CYP4A protein
levels.
PBBs also lowered the activities of hepatic peroxisomal
enzymes (Table 2). The two PBBs that are “co-planar” and
potent Ah receptor agonists, PBB-77 and PBB-169, both de-
creased peroxisomal beta-oxidation and FAO activity. PBB-
77 also lowered hepatic catalase activity. PBB-80 did not af-
fect any of the peroxisomal enzymes. As far as the effects
of selected PBBs on hepatic CYP4A protein levels are con-
cerned, only PBB-80 appeared to slightly increase CYP4A
protein (to 126% of control), whereas PBB-77 and PBB-169
substantially diminished total CYP4A protein.
Previous studies also found that peroxisomal β-oxida-
tion, catalase, and CYP4A were significantly suppressed in
the male rat following the administration of PCB-126 [31–
33]. The present study confirms these findings and extends
it to other PCBs and PBBs (PCB-122, PBB-77, PBB-169). In
contrast, Borlakoglu et al. [12] found an increase in CYP4A1
content in the livers of neonates which had been exposed to
PCBs via lactational transfer, although, in the same study,
the activity of catalase was unchanged, while peroxisomal
beta-oxidation and FAO activities were diminished. How-
ever, since a polyclonal antibody was used in an ELISA to
quantify CYP4A1 protein, there are certain questions about
the specificity of the antibody and the resulting quantitation.
In the present study, PCB-133 increased CYP4A protein lev-
els, while not affecting FAO and catalase activities.
Peroxisome proliferators lower serum and liver lipids
[34], whereas polyhalogenated biphenyls, particularly the Ah
receptor agonists, cause an increase in the neutral lipid con-
tent of the liver (i.e., fatty liver) [35, 36]. The results of
this investigation indicate that apparently neither the investi-
gated compounds themselves nor the accumulated hepatic
lipids were able to induce peroxisomal beta-oxidation and
increase CYP4A isozyme expression. Instead, the suppres-
sion of peroxisomal beta-oxidation and reduction of CYP4A-
mediated fatty acid omega-oxidation by certain polyhalo-
genated biphenyls (Ah receptor agonists) may be responsi-
ble to a considerable extent for the accumulation of hepatic
lipids.
The reduction in peroxisomal beta-oxidation is not likely
due to an inhibition of the individual enzyme activities by
congeneric polyhalogenated biphenyls or metabolites, but
rather due to a decrease in the amounts of these proteins, as
was demonstrated for CYP4A. The relatively short half-life
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of peroxisomal enzymes of 1.5 days [37] leaves open the pos-
sibilities that either certain polyhalogenated biphenyls func-
tion to downregulate the expression of these proteins or, al-
ternatively, their toxic action limits the ability of the cell to
synthesize new protein, or protein catabolism is increased.
These findings imply that the mechanism by which PCBs
and PBBs induce and promote hepatic tumors is different
from that of peroxisome proliferators. The induction of hep-
atic tumors by peroxisome proliferators is dependent on the
presence of PPARα [38]. Since PCBs and PBBs are not known
to alter the expression of PPARα itself, the absence of an in-
crease in the activities and levels of proteins associated with
PPARα indicates that these agents are exerting their carcino-
genic and promoting activities by some other mechanism.
Other mechanisms by which PCBs and PBBs may exert their
carcinogenic effects include altering other signal transduc-
tion pathways, increasing oxidative stress, influencing vita-
min A metabolism, and inhibiting metabolic cooperation
[9, 10].
In summary, the selected polyhalogenated biphenyls in
the present study did not increase the enzyme activities as-
sociated with peroxisomal beta-oxidation or the CYP4A pro-
tein content. In fact, one group of more acutely toxic con-
geners (the Ah receptor agonists) significantly decreased the
activities of catalase, fatty acyl-CoA oxidase, peroxisomal
beta-oxidation, and CYP4A content. Based on a range of
congeners with differing biologic properties tested, one may
conclude that the polyhalogenated biphenyls do not induce
peroxisome proliferation in the mature male rat.
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